Stock ADIL ADIAL PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Adial Pharmaceuticals, Inc.

Equities

ADIL

US00688A2050

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.69 USD +4.97% Intraday chart for Adial Pharmaceuticals, Inc. -11.05% -9.14%
Apr. 22 Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder MT
Apr. 12 Top Premarket Decliners MT

Evolution of the average Target Price on Adial Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d711cb4888d470ec0179f717ea152ad2._3N3mXDr-qzeHZI4nRluoc2W1fTwV97w0sH21KMlIzc.lhoTyQqKi_znZKZt7UsNyvXhvavCLbrC5JG75tBRFnSbNgToG6G73rFb3w~a0e01c5f4c0cd1e28cefe01df0d26a0f

Analyst Recommendations on Adial Pharmaceuticals, Inc.

Maxim Group Downgrades Adial Pharmaceuticals to Hold From Buy MT
Maxim Group Adjusts Adial Pharmaceuticals Price Target to $3 From $5, Maintains Buy Rating MT
ADIAL PHARMACEUTICALS : Litchfield Hills Adjusts Price Target on Adial Pharmaceuticals to $15 From $5, Maintains Buy Rating MT
ADIAL PHARMACEUTICALS : Litchfield Hills Initiates Coverage on Adial Pharmaceuticals With Buy Rating, $5 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.61 USD
Average target price
7.5 USD
Spread / Average Target
+365.84%
High Price Target
8 USD
Spread / Highest target
+396.89%
Low Price Target
7 USD
Spread / Lowest Target
+334.78%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Adial Pharmaceuticals, Inc.

Maxim
Litchfield Hills Research

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ADIL Stock
  4. Consensus Adial Pharmaceuticals, Inc.